<SEC-DOCUMENT>0001193125-24-223339.txt : 20240923
<SEC-HEADER>0001193125-24-223339.hdr.sgml : 20240923
<ACCEPTANCE-DATETIME>20240923092508
ACCESSION NUMBER:		0001193125-24-223339
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240923
DATE AS OF CHANGE:		20240923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276774
		FILM NUMBER:		241314966

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d836943d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774</FONT></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
February&nbsp;5, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>4,755,556 American Depositary Shares representing 47,555,560 Ordinary Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g836943g0921031900751.jpg" ALT="LOGO" STYLE="width:2.22014in;height:0.625694in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated February&nbsp;5, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-276774),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on September&nbsp;23, 2024 (the &#147;September 23, 2024 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have
attached the September&nbsp;23, 2024 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates
and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be
read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On September&nbsp;20, 2024, the last reported sale
price of the ADSs on Nasdaq was $0.3247 per ADS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#147;Risk Factors&#148; beginning on
page 9 of the Prospectus and the &#147;Risk Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the
Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal
offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is September&nbsp;23, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of September, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;</FONT> Form <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;23, 2024, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled, &#147;Kazia
Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium&#148;. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr.&nbsp;John
Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company&#146;s registration statements on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-276091</FONT> and <FONT
STYLE="white-space:nowrap">333-281937).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated September&nbsp;23, 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited </B>(Registrant)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date: 23&nbsp;September 2024</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g836917g0920231400068.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>23&nbsp;September 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Announces Presentation of EVT801 Clinical Data </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>at 15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Biennial Ovarian Cancer Research Symposium </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, September&nbsp;23, 2024 &#150; Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the
presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Biennial Ovarian Cancer Research Symposium, <FONT
STYLE="white-space:nowrap">co-presented</FONT> by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September&nbsp;21, 2024 in Seattle Washington. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;John Friend, CEO Kazia Therapeutics presented preliminary data from a Phase 1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial evaluating the safety and tolerability of EVT801, a highly selective small molecule VEGFR3 inhibitor targeting tumour angiogenesis. The
Phase 1 study met its primary objectives, with the maximal tolerated dose identified at 500mg twice a day (BID). The Phase 1 study also identified the recommended Phase 2 dose starting at 400mg BID. It was observed that EVT801 was tolerated across
all doses, with the majority of toxicities being mild to moderate and transient in nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key points of the presentation included: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A total of 26 patients were treated across 6 dosing cohorts ranging from 50mg once daily (QD) to 500mg twice
daily (BID) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patients with eleven different cancer types (ex. colon, renal cell, pancreatic) were enrolled in the study, with
heavily pretreated advanced ovarian cancer being the most prevalent indication (11 patients) </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Biomarkers have shown strong VEGFR3 expression in multiple indications, including ovarian cancer
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Encouraging clinical activity in High Grade Serous ovarian cancer patients with
<FONT STYLE="white-space:nowrap">forty-six</FONT> percent (46%) having stable disease or for at least three cycles, including two patients who received 9 cycles </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">One patient had a partial response <FONT STYLE="white-space:nowrap">(-39%</FONT> decrease) after 2 cycles of
EVT801 therapy </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr John Friend, CEO of Kazia Therapeutics,</B> commented: &#147;I was honored to participate at the Ovarian Cancer
Research Symposium and present our findings to fellow clinicians and ovarian cancer researchers from around the globe. Ovarian cancer is often diagnosed at late stages with poor patient prognosis, so the data from the Phase 1 study is extremely
encouraging and gives us confidence that we could potentially have a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">VEGFR-3</FONT> inhibitor with EVT801.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abstract: <B>Phase I study of EVT801, a <FONT STYLE="white-space:nowrap">VEGFR-3</FONT> inhibitor, shows promising clinical activity in HGS ovarian cancer</B>
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">https://www.xcdsystem.com/rivkin/program/ZR7NvO4/index.cfm?pgid=1697 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g836917g0920231400068.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;21, 2024 &#150; <FONT STYLE="white-space:nowrap">11:30am-1:30pm</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics
Limited (NASDAQ:<B>&nbsp;KZIA</B>) is an oncology-focused drug development company, based in&nbsp;Sydney, Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, an
investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this
disease. A completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in glioblastoma, GBM AGILE, has been completed with presentation of paxalisib arm data expected later in 2024 at a major
medical conference. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in&nbsp;February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA
in&nbsp;August 2020. Paxalisib was also granted FTD in&nbsp;July 2023&nbsp;for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric
Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in&nbsp;August 2020, and for atypical teratoid / rhabdoid tumours in&nbsp;June 2022&nbsp;and&nbsp;July 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in&nbsp;April 2021. Preclinical data has shown EVT801
to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research Symposium in
September 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit<B>&nbsp;www.kaziatherapeutics.com</B>&nbsp;or follow us on X @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any
statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801, the potential benefits of EVT801 as a
VEGFR3&nbsp;inhibitor and the potential market opportunity for EVT801. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and
uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to
regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC,
and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as
required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for release by Dr John Friend, CEO. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g836917g0920231400068.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g836917g0920231400068.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  .4# 2(  A$! Q$!_\0
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?_,2P[22OL^W]:^8M%%%8G2%%%% !1110 &BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g836943g0921031900751.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g836943g0921031900751.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ -(# 2(  A$! Q$!_\0
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MN;\+3ZE,UP+PRM&,;3+G.?;-=)652'LY<IM0JJM!32M<**;(2L;,.H!->-^
M/&_B#6?&5I8W]^9;>59"R;%&<(2.@]1246U<T<K.Q[-17F7Q&^(4NCS#2=%F
M O%(,\P ;R_]D>_KZ5TO@9=??1/M?B"Z:2>X(>.)D"F)?? ZG]*'%I7%S*]C
MJ***BN;F*SM9KF=PD,*%W8]@!DU)1+17FGP_\>SZ_P"(M2L;Y\"=C-9J?X%'
M5/RP?P->ETVFG9B335T%%%>/>*]?\=6OBB_@TU;W[&DF(O+MMRXP.AQS3C&X
M-V/8:*^=Y_B#XRM9V@N+^6*9?O(\*AA^&*]Q\,+J8\.6;:Q,9;]TWRDJ!C/(
M7CT! IR@XBC),UZ*BN':.VE=>&5"1^5>2?#GQGKVM^+%L]0OC-;F%V*%%'(Q
MCH*2BVKC<K.Q[!1114C"BO-OB-XZN/#^K:;8Z?)^\C<7%TH_B3LA^HS^E>A6
M5Y#J%C!>6[;X9XQ(C>H(S3<6E<2:;L3T444AG(ZK=:RGB );^;Y>Y?+51\I'
MO6MXDU2?1M':ZMH@\F\+R.%SW/\ GO69I?B"^N]<%M+&/+8L-H7E,4WQ=X@O
M=*N[>WM[='BD3<Q=-P;G&W]/UK7&-PBE)6TZ&6405>LY0?,F]GIL%A86OB^P
MM]2U*V*W"$QY4D!U!_ES_.NH:& F/<B93A,@<?2BV(-K$PC$>Y =@&-N1TKS
M6^U"ZNKV2661PVXX7.-OM1A<+[6^H9EF/L6M-+NROL=QJ'AO3=2U".]N8BTJ
M 9P>&QTS61X>\47VJZY-9W%L$C"L>!S'CL:U_#=W->:/&\Y+.K%=Q_B K$U?
M7[[3?%*6=K9(8F*!B$YDSC//^>E<U:'LI_/[ST,%4>*I<MKZ:7>Q:\3S:I%=
MP+9^:L)7.8AU;/?'X5T5H96LX#<#$QC&\>^.:S/$>HW&FV*26RC<S[2Q&=O%
M3:%?3ZAI:3W"XDW$9 QN'K7;--T4[*R/'IN,<5*/,VVKVZ(T)?\ 4R?[IKY;
MT+5[G0M474+0 SQQNJ$C.W<I7/X9S7U)+_J9/]TU\Z_#>U@OO&UI:W,:R0RQ
M3(Z,."#&U9T]F=-3=&O\+M"M/$'B"XU#4IUFDM2)5@<Y,C$_>/J ?UKW:OGG
M6M-U'X;^,([BS=O)W;[>0])$[JW\C7N/AW7[3Q)H\.H6C<,,.A/,;=P:*BOK
MT"&FAJUYM\7_ !#]AT6+1H'Q/>G=+@\B('^I_D:]'DD2*)Y)&"HBEF8] !U-
M?-7B+4;SQAXKN[RVADF!.(8U7)6->!Q^OU-*FKNXYNRL1+:ZIX2N]&UAD*-,
M@NH?<9^Z?J,?@U?26FZA!JNF6U_;-F&XC$B^V>WU'2OG_7;OQ;KMC#!J.GR&
M&V^:/;;[=@QC\L?RKM/@YXA\VUN-!G?YHLS6^3_"?O#\#S^)JZBNKD0=G8]6
MK.U[6(-!T2ZU*X(V0(2%S]YNP_$XK1KQ7XO^)?M>HQ:%;OF&U_>3X/60C@?@
M/YUE"/,[&DG97,OP'I,_C#QN^I7^9(H7^U7!/1F)^5?S_05[]7D'@3QCX6\+
M^'4MIIIOMDK>9<,L)/S=AGT _K7JFF:C;ZMIL%_:,6@G7<A88./I55+W%"UB
M6[_X\I_^N;?RKP;X1_\ (]1_]>\G\A7O-W_QY3_]<V_E7@WPC_Y'J/\ Z]Y/
MY"B'PL4_B1[_ %7OKR'3[">\N&VPP1F1S[ 9JQ7E_P 8O$/V;38-#@?$ER?-
MGP>D8/ _$_\ H-1%7=BY.RN>;2P:GXSU76-5C0NT<;74@_NH" %'T'3Z5Z5\
M'O$/VK3)]#G?,MJ?,AR>L9/(_ _^A5P7A^[\6:#:RC2["01W6&=FM]VX8X_#
MG]:HZ-?WWA'Q1:7]Q;R0,K;GC9=NZ,\,,?3/Y5T25U8P3L[GTU144-Q%<01S
M12*T<BAT8'@@C(-%<QT'.WWB"'3];:!+-#@@22 88Y]*N^*+Z73M':Z@MTFE
M5P%W+N"9[U-JMO8P1R:G-:K)+"N0?4]J@T/6_P"VA/%+ %* '&<@@UO5A[2E
MS05K;LYL-6]AB.6J[W=TO(?X;U.XU71TN;N,1RERO P&QW'^>U%WX:T^\N3.
MRNK,<L$. :R/%.CZS>ZA:OICE8$0+M1]@1LGG\L?E3?$>OZOI.IVEM;1"13&
MI8["?,;."!_GO7)"O*E??3KW/4JX&GBFN6SO=V['600Q6L*01*$11A5KD_#_
M (@U#5/$,MO=VB+&H8J=F#%CMFCQ!HVN7^NV]S93%(=JXQ)CRCWR.]=/>3QV
M%G/=^6"47<<#EJ/?J3^?W@_8X>C=V=U_X#8R?$&N_P!FSQVPMDEWKO;?TQG'
M]*V;.5)[*&:--BN@8+C&,U@Z9?6WB25X[VR0O"-RG)Z9KI%4*H50 H& !VKK
MJI02A:S6YY&&E*I)U5*\7L! 92IZ$8-<CH7PYT;P_J\6I6CW!FB#!0[Y'((/
MZ&NOJA#J$DD]S&]L4%N,LVX'/&1^E914FG8Z92BFKD'B'P[I_B73OL>H1DH&
M#HZG#*?8U3\,^#M/\*O<-82W!6< ,DCY''?'K6I!JD-P]JB8+3QE\ _=P <'
M\Z2RU$WCR8AVHFX;MX)X..G6JY9I$JK3;5F2:II\>JZ7<6$SND=PA1VC.#@]
M:QO#/@C2?"L\\]B)6EF4(7D;) ZX'^>U:>GZJ+V1$,)C+Q>:AW Y''ITZU/;
M7T5U<W$"9W0-@^_N/QR/PI.,XW01J4Y6:>Y9(!&",@]17(Z9\.=&T?74U:R>
MXCF1V94#_+SG(^G-;EIJZW3%3"R?NVD4[@<@'!^E$&K&73YKQH-L<<7F !P2
M>,XXZ4^2:%[:G*SN:=<)>?"C0KZ]GNYIKLRS2-(Q\SN3FNQ-X3<- D99Q")0
M,XSDD8_2J\>J,U@UV]NR*'" ;@<_-M/ZT*,UL.52'7^K''_\*>\._P#/6[_[
M^5VNDZ9!HVE6^G6Q8PVZ;5+')I)K]Q=/!;VSSM$ 9""!MST'/4TK7Y&HBT6$
MDX#,VX# .>@[]*&IO<.>">GH6W021LC?=8$&N4\/?#W2/#>J#4+-YVF"%!O?
M(P:ZVBH3:-+(*Y#6?AUH^NZV^J7TER\KE<H'^7  &/IQ77T4)M; TGN(JJB*
MB@!5& !V%<[XF\%Z7XK>WDOQ(LD (5XVP2#V-='10FUL-JYR47@&S@ACACU/
M4UCC4*JB?@ < 45UM%',Q<J&R1I+&T<BAD88(/0BL34[8Z1H\S:3!Y;LPWE1
MD@>O-;E%5";B_+L9U:2FGT??JCG='U6XAT.:\U+>4C;",1\S#_\ 75ZPURTU
M"TGN-K)]G&YPPY P>1^1JQJD,<^EW"2J&783CW'(K)\+6L#:+*6C!\YBLF?X
MAZ?J:W?LYPE-JSN<L?;4ZL:2E=6>^_\ 6Q:T[Q!#JC3Q6\;K,B%D#]&_SQ67
MH%QJEUJ4T-Z))(&5A*LB\ _Y[5+X5MH4FO)%0!U;8#GH/3]*Z>G4E"G*4(K<
MFA"I7C"I.6U]NI7M-/M;$,+:!8]Q^;'>K-)17*VV[L]",5%6BK(6JPM%$ET^
M\_Z1C/'3"XJQ10FUL#BGN4H-+AMWM7C"AH(S&2% WY &3^7ZTEEIILWD(E#*
M^[CRP#R<]>]7J*KVDGU(5&"=TBA9:5'8',#X)A$;?*.2.C?6DM-(CLYHI8I9
M"RJ5?<<[\\_ASS6A10ZDG?7<2H4U:RV*EIIL%I;&*-5W,"&D"@%L^M16NE+!
M926CR!XGC\OY8PIQC'7N:T**/:2[C]C#338IV=BUO*TTL[32%!&"5 PH[?K2
M?V<O]G?8_,.WS-^['^WO_P#K5=HI<\KW!4H)6M_3*4U@[73SV]T\#2 "0!0=
MV.AYZ&EN=/-S=PS-,0L3!PH49R/?K@]ZN44^>0.E!BT4E%0:"T4E% "T4E%
'"T4E% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
